Table 2.

FDA approved COVID-19 mRNA vaccines [71,72].

Name	mRNA Specific to	LNP Composition	Adverse Effects
BNT162b2	Spike glycoprotein of SARS-CoV-2	lipids ((4- hydroxybutyl)azanediyl) bis(hexane-6,1- diyl)bis(2- hexyldecanoate), 2 [(polyethylene glycol)- 2000]-N,Nditetradecylacetamide, 1,2-distearoyl-snglycero- 3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose	Myocarditis Pericarditis
mRNA- 1273	Spike glycoprotein of SARS-CoV-2	LNP: Proprietary Ionic lipid SM-102, polyethylene glycol (PEG) 2000, dimyristoylglycerol (DMG), cholesterol, 1,2- distearoyl-sn-glycero-3- phosphocholine [DSPC]), tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose	Myocarditis Pericarditis
LUNARCOv- 19 (ARCT- 021)	Self-replicating mRNA specific to Spike glycoprotein of SARS-CoV-2	Arcturus Therapeutics proprietary ionizable lipid, DSPC, cholesterol, and PEG2000-DMG dissolved in ethanol	NA

NA: not available.